萊美藥業(300006.SZ):定增申請收到深交所落實函
格隆匯 11 月 13日丨萊美藥業(300006.SZ)公佈,公司於2020年11月13日收到深圳證券交易所出具的《關於重慶萊美藥業股份有限公司申請向特定對象發行股票的審核中心意見落實函》(審核函〔2020〕020311號)(“落實函”)。
根據《證券法》《創業板上市公司證券發行註冊管理辦法(試行)》《深圳證券交易所創業板上市公司證券發行上市審核規則》等有關規定,深交所發行上市審核機構對公司向特定對象發行股票的申請文件進行了審核,認為公司符合發行條件、上市條件和信息披露要求,現需要公司就有關事項予以落實並提交回復,回覆內容需通過臨時公告方式披露,並要求公司在回覆內容披露後及時報送募集説明書(註冊稿)及相關文件,同時報送誠信記錄核查表,並在收到《審核中心意見告知函》十個工作日內彙總補充報送與審核問詢回覆相關的保薦工作底稿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.